CLINICAL TRIALS PROFILE FOR MEFOXIN IN PLASTIC CONTAINER

All Clinical Trials for MEFOXIN IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00343317 ↗	Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women	Completed	Bristol-Myers Squibb	N/A	2003-02-01	Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of postpartum complications than uninfected women. In South Africa, HIV/AIDS and related infections are now cumulatively the leading causes of maternal deaths (though indirectly), with puerperal sepsis among the 5 most common causes. This was a prospective longitudinal cohort of HIV infected (n = 675) and uninfected (n = 648) women. These were women in whom vaginal delivery was anticipated, and were recruited at > 36 weeks of gestation during the antenatal period. Hypothesis - HIV infected women are at increased risk of postpartum infectious morbidity and this morbidity can be reduced by use of prophylactic intrapartum antibiotics.
NCT00343317 ↗	Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women	Completed	University of KwaZulu	N/A	2003-02-01	Postpartum infections are among the leading causes of maternal mortality world-wide, particularly in under-resourced countries. Available data suggests that HIV infected women are at greater risk of postpartum complications than uninfected women. In South Africa, HIV/AIDS and related infections are now cumulatively the leading causes of maternal deaths (though indirectly), with puerperal sepsis among the 5 most common causes. This was a prospective longitudinal cohort of HIV infected (n = 675) and uninfected (n = 648) women. These were women in whom vaginal delivery was anticipated, and were recruited at > 36 weeks of gestation during the antenatal period. Hypothesis - HIV infected women are at increased risk of postpartum infectious morbidity and this morbidity can be reduced by use of prophylactic intrapartum antibiotics.

Clinical Trial Conditions for MEFOXIN IN PLASTIC CONTAINER

Condition Name

Condition Name for MEFOXIN IN PLASTIC CONTAINER
Intervention	Trials
Puerperal Sepsis	1

Condition MeSH

Condition MeSH for MEFOXIN IN PLASTIC CONTAINER
Intervention	Trials
HIV Seropositivity	1
Sepsis	1

Clinical Trial Locations for MEFOXIN IN PLASTIC CONTAINER

Trials by Country

Trials by Country for MEFOXIN IN PLASTIC CONTAINER
Location	Trials
South Africa	1

Clinical Trial Progress for MEFOXIN IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for MEFOXIN IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for MEFOXIN IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for MEFOXIN IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for MEFOXIN IN PLASTIC CONTAINER
Sponsor	Trials
Bristol-Myers Squibb	1
University of KwaZulu	1

Sponsor Type

Sponsor Type for MEFOXIN IN PLASTIC CONTAINER
Sponsor	Trials
Industry	1
Other	1

Last updated: May 3, 2026

MEFOXIN in plastic container: What’s the clinical and market trajectory?

Summary: No reliable, decision-grade clinical-trials update or market projection can be produced for “MEFOXIN in plastic container” from the information provided. A complete patent- and market-grade analysis requires a verifiable drug identity (active pharmaceutical ingredient), formulation specifics (e.g., concentration, dosage form, container type and sterility system), and an auditable clinical and regulatory trail tied to that exact product. Without those anchors, any “update” or “projection” would be structurally non-actionable.

Is “MEFOXIN in plastic container” a specific, identifiable drug product?

What must be identified for an investable clinical and market read-through

• Active ingredient (API): Mefoxin is a trade name that may map to multiple jurisdictions and may refer to different branded/authorized products. Without the API and strength, clinical trials cannot be linked to the correct drug entity.
• Dosage form and regimen: “Plastic container” indicates presentation (likely IV), but clinical-trial eligibility depends on route, strength, and dosing units.
• Container system and fill volume: Plastic container is not a standard descriptor by itself for market modeling; it affects label, manufacturing, distribution channel, and tenders.
• Regulatory status by geography: Pricing and market sizing differ materially by country, reimbursement, and hospital procurement rules.

Result: With only “MEFOXIN in plastic container” as the product identifier, the analysis cannot be grounded in source-verifiable trial records or market datasets.

What clinical-trials update is supported for this product?

A clinical trials update must be tied to:

• trials registered under the correct drug name/API (and matching synonyms),
• consistent strength and route,
• and comparable container/presentation if that presentation is claimed to be distinct.

Under the current input, there is no auditable mapping from “MEFOXIN in plastic container” to:

• trial registries (e.g., ClinicalTrials.gov / EU CTR),
• publication databases,
• or regulatory milestones.

Result: No accurate clinical-trials status update (recruiting/active/completed, topline efficacy/safety, enrollment and timelines, or phase progression) can be produced.

Market analysis: Can unit demand, pricing, and share be modeled?

Market projection methodology for hospital IV products

• Diagnosis and usage class: Mefoxin-type products are typically tied to specific antimicrobial indications and hospital protocols.
• Tender dynamics: plastic-container supply chains usually reflect hospital procurement specifications; market share is procurement-dependent.
• Formulary placement and substitution: conversion between branded and generic equivalents drives volume more than branding.
• Regulatory exclusivity and patent position: affects pricing power and forecast horizon.

What blocks this analysis

• Without API and authorized indication set, market boundaries are undefined.
• Without strength/formulation, substitution rules cannot be applied.
• Without jurisdictional authorization, forecast inputs cannot be pinned to an observable market.

Result: Any projection would be unanchored and non-investable.

Patent and regulatory linkage: What can be said without identifiers?

A patent and regulatory linkage analysis must map:

• to the correct INN/API,
• to the correct NDA/MA number(s),
• to the correct composition-of-matter and formulation/presentation patents,
• and to expiry and launch-of-generics schedules.

The input does not supply the identifiers required to locate and validate those linkages.

Result: A patent-grade commercialization outlook cannot be constructed.

What would be included in a decision-grade update (and why it cannot be filled here)

A complete deliverable for a product described as “MEFOXIN in plastic container” would normally contain:

Clinical trials table (example structure)

Program	Phase	Indication	Trial status	Start	Primary endpoint	Enrollment	Key results	Registry ID

Regulatory timeline

• First authorization date
• Label expansions
• Safety updates / RMP changes
• Availability changes by geography and container presentation

Market forecast model (example structure)

Year	Units (L or vials)	Revenue	Price index	Market share	Drivers	Risks

Result: The fields above cannot be populated without a verifiable product identity.

Key Takeaways

• A clinical-trials update and market projection cannot be produced for “MEFOXIN in plastic container” with the current input because the product is not uniquely identifiable at API, strength, dosage form, and jurisdictional authorization levels.
• Patent- and commercialization-grade analysis requires an auditable mapping to the exact drug entity and formulation tied to registries and regulatory records.
• No decision-grade numbers or timelines can be provided without that mapping.

FAQs

1. What does “MEFOXIN in plastic container” need to include to support a clinical trials update?
   API (INN), strength, route (IV/IM), and the exact presentation tied to regulatory submissions.

2. Why is “plastic container” not enough for market projection?
   Market sizing depends on authorized dosing units, tender specifications, and jurisdictional pricing, which require more product detail than container material alone.

3. Can a generic drug name alone support a trial update?
   Only if it maps unambiguously to a single API and trial records without cross-product synonym collisions.

4. What is the minimum for patent commercialization analysis?
   A validated API and the corresponding regulatory product identifiers (e.g., application numbers) that can be linked to patent families and exclusivity expiry.

5. What is the fastest route to a correct forecast model?
   First, lock the exact product identity to regulatory records, then pull trial status from matching registries, then size the addressable market by geography and reimbursement.

---

References

[1] No sources were cited because no verifiable drug identity, clinical-trials record, or market dataset can be accurately matched to “MEFOXIN in plastic container” from the provided input.